13 February 2018 - - Golden, Colorado-based injection technology specialist PharmaJet's needle-free injection system will continue to be used in Vaccibody AS' expanded human clinical trial (phase IIa) for the study of an Human papillomavirus (HPV) disease a vaccine, the company said.
Vaccibody, a biopharmaceutical company focused on the development of novel immunotherapies, reported successful clinical trial results last year of their therapeutic DNA vaccine (VB10.16) delivered with PharmaJet's needle-free injection technology.
The innovative Stratis Injector has US FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.
PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The PharmaJet Needle-free Injectors are safe, fast and easy-to-use.
They eliminate needle stick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal.